Congress Wealth Management’s Maze Therapeutics MAZE Stock Holding History

Congress Wealth Management’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$371K	Buy	+30,235	New	+$315K	﹤0.01%	1010

Other funds holding MAZE

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

General Catalyst Group Management Cambridge, Massachusetts $189M AUM 10.96% 1-Year Est. Return

Congress Wealth Management's MAZE Position: Q2 2025 in Review

Congress Wealth Management opened a new position in Maze Therapeutics (MAZE) in Q2 2025: 30,235 shares worth $371K. The stake represents ﹤0.01% of the portfolio and ranks #1010 among its holdings.

75 funds tracked by Wall St. Rank hold MAZE as of Q2 2025.

Congress Wealth Management held 30,235 shares of Maze Therapeutics worth $371K as of Q2 2025.
Maze Therapeutics was a new Congress Wealth Management position in Q2 2025.
Maze Therapeutics made up ﹤0.01% of Congress Wealth Management's portfolio in Q2 2025, its #1010 holding.
75 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2025.

Based on Congress Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.